Genomic strategies for personalized cancer therapy

被引:37
作者
Garman, Katherine S. [1 ]
Nevins, Joseph R. [1 ]
Potti, Anil [1 ]
机构
[1] Duke Univ, Med Ctr, Duke Inst Genome Sci & Policy, Durham, NC 27710 USA
关键词
D O I
10.1093/hmg/ddm184
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Numerous recent studies have demonstrated the use of genomic data, particularly gene expression signatures, as clinical prognostic factors in cancer and other complex diseases. These studies highlight the opportunity for strategies to achieve truly personalized cancer treatment. In particular, the ability to develop gene expression signatures will likely allow us to guide the use of currently available cancer drugs, develop new targeted therapeutics, and provide an opportunity to better match the most effective drug or drugs with the molecular characteristics of the individual patient.
引用
收藏
页码:R226 / R232
页数:7
相关论文
共 36 条
  • [1] Phase II study of the farnesyl transferase inhibitor r115777 in patients with advanced non-small-cell lung cancer
    Adjei, AA
    Mauer, A
    Bruzek, L
    Marks, RS
    Hillman, S
    Geyer, S
    Hanson, LJ
    Wright, JJ
    Erlichman, C
    Kaufmann, SH
    Vokes, EE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) : 1760 - 1766
  • [2] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    Alizadeh, AA
    Eisen, MB
    Davis, RE
    Ma, C
    Lossos, IS
    Rosenwald, A
    Boldrick, JG
    Sabet, H
    Tran, T
    Yu, X
    Powell, JI
    Yang, LM
    Marti, GE
    Moore, T
    Hudson, J
    Lu, LS
    Lewis, DB
    Tibshirani, R
    Sherlock, G
    Chan, WC
    Greiner, TC
    Weisenburger, DD
    Armitage, JO
    Warnke, R
    Levy, R
    Wilson, W
    Grever, MR
    Byrd, JC
    Botstein, D
    Brown, PO
    Staudt, LM
    [J]. NATURE, 2000, 403 (6769) : 503 - 511
  • [3] Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer
    Arango, D
    Laiho, P
    Kokko, A
    Alhopuro, P
    Sammalkorpi, H
    Salovaara, R
    Nicorici, D
    Hautaniemi, S
    Alazzouzi, H
    Salovaara, R
    Nicorici, D
    Hautaniemi, S
    Alazzouzi, H
    Mecklin, JP
    Järvinen, H
    Hemminki, A
    Astola, J
    Schwartz, S
    Aaltonen, LA
    [J]. GASTROENTEROLOGY, 2005, 129 (03) : 874 - 884
  • [4] Oncogenic pathway signatures in human cancers as a guide to targeted therapies
    Bild, AH
    Yao, G
    Chang, JT
    Wang, QL
    Potti, A
    Chasse, D
    Joshi, MB
    Harpole, D
    Lancaster, JM
    Berchuck, A
    Olson, JA
    Marks, JR
    Dressman, HK
    West, M
    Nevins, JR
    [J]. NATURE, 2006, 439 (7074) : 353 - 357
  • [5] Linking oncogenic pathways with therapeutic opportunities
    Bild, Andrea H.
    Potti, Anil
    Nevins, Joseph R.
    [J]. NATURE REVIEWS CANCER, 2006, 6 (09) : 735 - U13
  • [6] Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial
    Bogaerts, Jan
    Cardoso, Fatima
    Buyse, Marc
    Braga, Sofia
    Loi, Sherene
    Harrison, Jillian A.
    Bines, Jacques
    Mook, Stella
    Decker, Nuria
    Ravdin, Peter
    Therasse, Patrick
    Rutgers, Emiel
    van't Veer, Laura J.
    Piccart, Martine
    [J]. NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (10): : 540 - 551
  • [7] Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer
    Chang, JC
    Wooten, EC
    Tsimelzon, A
    Hilsenbeck, SG
    Gutierrez, MC
    Elledge, R
    Mohsin, S
    Osborne, CK
    Chamness, GC
    Allred, DC
    O'Connell, P
    [J]. LANCET, 2003, 362 (9381) : 362 - 369
  • [8] Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance
    Cleator, S
    Tsimelzon, A
    Ashworth, A
    Dowsett, M
    Dexter, T
    Powles, T
    Hilsenbeck, S
    Wong, H
    Osborne, CK
    O'Connell, P
    Chang, JC
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2006, 95 (03) : 229 - 233
  • [9] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
    Cobleigh, MA
    Vogel, CL
    Tripathy, D
    Robert, NJ
    Scholl, S
    Fehrenbacher, L
    Wolter, JM
    Paton, V
    Shak, S
    Lieberman, G
    Slamon, DJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2639 - 2648
  • [10] RETRACTED: An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer (Retracted article. See vol. 30, pg. 678, 2012)
    Dressman, Holly K.
    Berchuck, Andrew
    Chan, Gina
    Zhai, Jun
    Bild, Andrea
    Sayer, Robyn
    Cragun, Janiel
    Clarke, Jennifer
    Whitaker, Regina S.
    Li, LiHua
    Gray, Jonathan
    Marks, Jeffrey
    Ginsburg, Geoffrey S.
    Potti, Anil
    West, Mike
    Nevins, Joseph R.
    Lancaster, Johnathan M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) : 517 - 525